Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 75%Moderate 1 · 25%High 0 · 0%

Atovaquone‐proguanil vs artesunate‐atovaquone‐proguanil

Total failure day 28 PCR‐unadjusted · children and adults

Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐unadjusted compared with artesunate‐atovaquone‐proguanil (low certainty).

1 finding from 1 review

Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes only
RR 15.48 [0.9, 267.27]
1 study · 187 participants
Low

Atovaquone‐proguanil vs artesunate‐atovaquone‐proguanil

Total failure day 42 PCR‐unadjusted · children and adults

Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐unadjusted compared with artesunate‐atovaquone‐proguanil (moderate certainty).

1 finding from 1 review

Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes only
RR 1.56 [0.88, 2.79]
1 study · 1063 participants
Moderate

Atovaquone‐proguanil vs artesunate‐amodiaquine (AS‐AQ)

Total failure day 28 PCR‐unadjusted · children under 5 years of age

Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐unadjusted compared with artesunate‐amodiaquine (low certainty).

1 finding from 1 review

Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes only
RR 1.2 [0.49, 2.91]
1 study · 132 participants
Low

Atovaquone‐proguanil vs mefloquine plus artesunate (MQ + AS)

Total failure day 42 PCR‐unadjusted · children and adults

Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐unadjusted compared with artesunate‐mefloquine (low certainty).

1 finding from 1 review

Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes only
RR 0.8 [0.5, 1.3]
1 study · 1063 participants
Low